<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01192802</url>
  </required_header>
  <id_info>
    <org_study_id>Albendazole-001</org_study_id>
    <nct_id>NCT01192802</nct_id>
  </id_info>
  <brief_title>Efficacy of Albendazole to Treat Intestinal Helminths and Its Effect on Gut Microflora</brief_title>
  <official_title>Effect of Intestinal Helminths on Gut Microflora</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Schweitzer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albert Schweitzer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Albendazole is a main anti-helminth, however there is a lack of data regarding its efficacy
      in the school children population. The aim of this study is to evaluate the efficacy of the
      albendazole one versus two and three doses, in school children infected with intestinal
      helminth.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>parasite cleared and reduced up to 80% at day 42</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of major gut bacteria</measure>
    <time_frame>42 days</time_frame>
    <description>Change in the prevalence of major gut bacteria after antihelminth treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Intestinal Diseases</condition>
  <condition>Helminthiasis</condition>
  <arm_group>
    <arm_group_label>1 dose, Albendazole , tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2 doses, albendazole, tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 tablet of 400 mg of albendazole per day for two consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 doses albendazole, 400mg, tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albendazole</intervention_name>
    <description>1 tablet of 400 mg of albendazole per day for three consecutive days</description>
    <arm_group_label>3 doses albendazole, 400mg, tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albendazole</intervention_name>
    <description>single 1 tablet of 400 mg of albendazole</description>
    <arm_group_label>1 dose, Albendazole , tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albendazole</intervention_name>
    <description>1 tablet of 400 mg of albendazole per day for two consecutive days</description>
    <arm_group_label>2 doses, albendazole, tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presence of intestinal helminths eggs in the stool

        Exclusion Criteria:

          -  allergy to imidazole derivate

          -  No intestinal helminths
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical research Unit of Lambaréné</name>
      <address>
        <city>Lambarene</city>
        <state>Moyen ogooue</state>
        <zip>118</zip>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Gabon</country>
  </location_countries>
  <link>
    <url>http://www.lambarene.org</url>
    <description>Medical Research Unit of the Albert Schweitzer Hospital</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2010</study_first_submitted>
  <study_first_submitted_qc>August 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <name_title>Dr Ayola Akim ADEGNIKA</name_title>
    <organization>Medical Research Unit</organization>
  </responsible_party>
  <keyword>albendazole</keyword>
  <keyword>ascaris</keyword>
  <keyword>trichiurus</keyword>
  <keyword>hookworms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Helminthiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albendazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

